Verrica Pharmaceuticals Inc. is in an anticipatory mode, awaiting a 13 July action date for VP-102, its formulation of cantharidin that is in position to become the first approved therapy in the US for molluscum contagiosum. CEO Ted White said the company plans to focus its marketing efforts on pediatric dermatologists, who because they mainly are based at medical institutions cannot use the compounded cantharidin typically given to molluscum patients.
During the Winter Clinical Dermatology Conference in Hawaii from 18-22 January, Verrica presented a pooled analysis of a combined 528 patients from its two successful Phase III CAMP studies that demonstrated VP-102 can completely clear molluscum lesions at sites all over a patient’s body with statistical significance compared to vehicle. The Philadelphia-area firm first presented positive data from the CAMP-1 and CAMP-2 trials in January 2019
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?